IL-1⍺ blockade is a novel interesting target in atopic dermatitis (AD). In a proof-of-concept study, an IL-1 blocker improved AD in all disease measures .
“The rationale behind targeting IL-1⍺ is that Th1 immunity plays a signifying role in adults with chronic AD,” said Prof. Alice Gottlieb (Icahn School of Medicine at Mount Sinai, USA). Under the influence of a variety of cytokines, including IL-17A and IL-17C, keratinocytes increase release of IL-1⍺. This cytokine drives leukocyte recruitment and activates the vascular endothelium . By potentiation of nociceptors, itch is increased. It stimulates expression of matrix metalloproteinases, thus impairing the skin barrier . This results in skin inflammation, epidermal barrier defects, and severe, debilitating itch, and these factor are all hallmarks of AD [4,5]. IL-1⍺ on circulating leukocytes may also drive inflammatory signalling in the microvasculature of lesions. In addition, it induces breakdow...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« IL-4/IL-13 blockade leads to rapid itch reduction in adolescents Next Article
Rituximab beats mycophenolate mofetil in pemphigus vulgaris »
Table of Contents: EADV 2019
Spotlight on Psoriasis
New Insights in Photoprotection
Rosacea – from new spectrum to new therapy
Best of the Posters
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.